Our myopia management portfolio continued to strengthen, including MiSight growing 82% to 3 million and CooperSurgical posted a very strong quarter with Paragard growing 16% and fertility 10%.
And lastly, we're incredibly busy with our myopia management portfolio of MiSight and Ortho-k lenses, which grew 46% for the quarter to 12 million.
